MXC: $0.11
What We Change

Holding unique IP, MGC Pharmaceutical’s Innovation division puts the Company at the forefront of exploration and development for indications that will serve large global markets.

As part of the Innovation division, MGC Pharma will be working on GMP certification and start clinical studies in epilepsy, based in Slovenia, in addition to ongoing advancement of supplement and neutraceutical products. MGC also hopes to offer patients in Australia with these products and generate revenue from API sales.

Research and Development
  • Longstanding clinical studies in Neurological disorders with Pro Uri Kramer and Dr. David Neubauer
  • Large pool of clinical data via management and advisory expertise
  • Unique patient care with Medical Cannabis
Business Development

Innovation Division: We will be working on GMP certification and commence clinical studies in epilepsy in Slovenia as well as continuing to work on the development of neutraceuticals and supplement products. We are also working on being able to provide patients in the Australian market with these products and generate revenue from API sales.

Projects
  • GMP Cleanroom Manufacturing
  • Active Analytical Laboratories operational
  • Sales and Production of the API worldwide
Partners

Lenis: MGC Pharmaceuticals Ltd has signed a 5-year, Supply and Distribution Agreement with European pharmaceutical distribution company, Lenis farmacevtika d.o.o. (Lenis).

Epilepsy Foundation: MGC Pharmaceuticals Ltd has signed a collaboration agreement with Australia’s leading Epilepsy association on future joint clinical trials.

HL Pharma: MGC Pharmaceuticals Ltd Australian Supply and Distribution company.

view all partners